This study intends to recruit within 6 months of clinical practice in the Greek reality regarding the data administration of eplerenone in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with dysfunction left ventricle (LVEF ≤ 40%) and clinically proven heart failure after recent myocardial infarction.